However, this finding was controversial, as Shujing et al. [55] identified a connection between SOX3 upregulation and poorer patient outcomes in glioma, highlighting the complex role of SOX3 in glioblastoma and glioma pathology (Table 1). The gene discussed is SOX3; the disease is central nervous system cancer.